Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX).

Full DD Report for BCRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: BCRX)

BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. Ms. Heggie currently serves as senior vice president, head of Europe, Canada, Middle Eas...
Source: GlobeNewswire
Date: November, 20 2018 07:00
BioCryst's (BCRX) CEO Jon Stonehouse on Q3 2018 Results - Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2018 Results Earnings Conference Call November 6, 2018, 8:30 AM ET Executives John Bluth - IR Jon Stonehouse - CEO, Tom Staab - CFO Dr. Bill Sheridan - Chief Medical Officer Lynne Powell - Chief Commercial Officer Analysts Maury ...
Source: SeekingAlpha
Date: November, 06 2018 12:59
BioCryst Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 06 2018 08:36
BioCryst Pharmaceuticals misses by $0.01, misses on revenue
BioCryst Pharmaceuticals (NASDAQ: BCRX ): Q3 GAAP EPS of -$0.28 misses by $0.01 . More news on: BioCryst Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 07:04
BioCryst Reports Third Quarter 2018 Financial Results
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the third quarter ended September 30, 2018. “With enrollment in ...
Source: GlobeNewswire
Date: November, 06 2018 07:00
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November...
Source: GlobeNewswire
Date: November, 05 2018 07:00
Week 45 Breakout Forecast: Short-Term Picks To Give You An Edge
2018 YTD Chart: +56.48% New High YTD Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 45: The Momentum Gauges finally showed some improvement after deteriorating since week 39. The positive momentum gauge increased slightly to 18 this week from a ...
Source: SeekingAlpha
Date: November, 05 2018 02:06
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease Control and Prevention (CD...
Source: GlobeNewswire
Date: September, 06 2018 07:00
CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
—Safety and efficacy data support advancement of 750 mg dose as first oral therapy for acute HAE attacks— In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), please note that in the first line of the table, the value...
Source: GlobeNewswire
Date: September, 04 2018 12:15
BioCryst's BCX7353 shows positive action in mid-stage HAE study; shares up 5% premarket
BioCryst Pharmaceuticals (NASDAQ: BCRX ) is up  5%  premarket on light volume in response to its announcement of positive results from an exploratory Phase 2 clinical trial evaluating three oral doses of BCX7353 in patients with hereditary angioedema (HAE). More news on: BioC...
Source: SeekingAlpha
Date: September, 04 2018 07:58

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-129.008.979.118.74276,821
2018-12-119.168.879.178.76220,735
2018-12-108.799.039.178.65292,937
2018-12-078.948.729.228.705386,677
2018-12-068.918.939.168.6562445,599

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1219,34278,55924.6210Cover
2018-12-1133,43060,75655.0234Short
2018-12-1038,949102,95837.8300Short
2018-12-0778,218101,65276.9468Short
2018-12-06104,169193,34453.8775Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BCRX.


About BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Logo for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

Not available

 

Contact Information

 

 

Current Management

  • Charles E. Bugg / President, CEO
  • John A. Montgomery / Secretary

Current Share Structure

  • Market Cap: $592,622,721 - 05/14/2018
  • Issue and Outstanding: 98,606,110 - 01/31/2018

 


Recent Filings from (NASDAQ: BCRX)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 10 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 08 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: April, 10 2018
Filing of certain prospectuses and communications in connection with business combination transactions
Filing Type: 425Filing Source: edgar
Filing Date: April, 10 2018

 

 


Daily Technical Chart for (NASDAQ: BCRX)

Daily Technical Chart for (NASDAQ: BCRX)


Stay tuned for daily updates and more on (NASDAQ: BCRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BCRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BCRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BCRX and does not buy, sell, or trade any shares of BCRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/